1998
DOI: 10.1016/s0959-8049(97)10162-9
|View full text |Cite
|
Sign up to set email alerts
|

The evidence for tamoxifen and chemotherapy as treatment for metastatic melanoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
7
0
1

Year Published

2002
2002
2024
2024

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 16 publications
(8 citation statements)
references
References 20 publications
0
7
0
1
Order By: Relevance
“…Several phase II trials were conducted with the anti-oestrogen tamoxifen as a single agent or combined with chemotherapy (reviewed by Rusthoven [4]), with contradictory results.…”
Section: Introductionmentioning
confidence: 99%
“…Several phase II trials were conducted with the anti-oestrogen tamoxifen as a single agent or combined with chemotherapy (reviewed by Rusthoven [4]), with contradictory results.…”
Section: Introductionmentioning
confidence: 99%
“…Tamoxifen has been used in clinical trials for patients with melanoma since the late 1970s. Initially it showed promise as a single agent and then was combined with chemotherapy in 1984 (Rusthoven 1998). Since then, a number of phase II clinical trials have combined tamoxifen with different chemotherapeutic agents with overall response rates ranging from 8% to 60%.…”
Section: Serms and Skin Biologymentioning
confidence: 99%
“…Since then, a number of phase II clinical trials have combined tamoxifen with different chemotherapeutic agents with overall response rates ranging from 8% to 60%. However, treatment of melanoma with tamoxifen still remains controversial, since it is still unclear whether the strength of evidence from the randomized trials outweighs the combined evidence from numerous nonrandomized trials (Rusthoven 1998).…”
Section: Serms and Skin Biologymentioning
confidence: 99%
“…For women with ER-positive breast tumors, tamoxifen results in a 50% annual reduction in the recurrence rate and a 28% annual reduction in the death rate [115,116]. Women with metastatic disease who have ER-positive tumors also benefit from treatment with tamoxifen [117]. In addition, findings that tamoxifen could reduce the incidence of contralateral breast cancer led to breast cancer prevention trials [118].…”
Section: Tamoxifen and Sermsmentioning
confidence: 99%